ASPM介导的AURKA表达和活性调节在胶质瘤Epothilone B化疗抵抗中的作用及机制研究

批准号:
81903663
项目类别:
青年科学基金项目
资助金额:
20.0 万元
负责人:
曾文静
依托单位:
学科分类:
H3505.抗肿瘤药物药理
结题年份:
2022
批准年份:
2019
项目状态:
已结题
项目参与者:
--
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
脑胶质瘤是最常见的中枢神经系统原发性恶性肿瘤,因其侵袭性强和放化疗抵抗的特点,患者预后差。本项目前期实验发现人类异常纺锤体样小头畸形相关蛋白(ASPM)可促进胶质瘤细胞增殖和迁移;文献报道ASPM可与激酶AURKA结合,而我们发现胶质瘤组织中AURKA与ASPM表达呈正相关,干扰胶质瘤细胞中ASPM表达可下调AURKA蛋白表达,增加Epothilone B(EpoB)敏感性。因此本项目拟通过临床研究,查明ASPM和AURKA表达与胶质瘤患者预后及胶质瘤细胞EpoB敏感性的相关性;并应用蛋白免疫共沉淀和GST-pulldown实验,查明胶质瘤细胞中ASPM与AURKA蛋白相互作用;最后通过细胞和动物实验,阐明ASPM介导的AURKA表达和活性调节在胶质瘤EpoB化疗抵抗中的作用。本研究有助于为胶质瘤的治疗提供新的靶点,并为基于ASPM表达水平胶质瘤患者EpoB的个体化治疗奠定重要的理论依据。
英文摘要
Glioma is the most common primary malignant tumor of the central nervous system. However, the molecular mechanism of the progression and chemotherapy resistance of glioma remains unclear. In our previous study, we found that human abnormal spindle microcephaly related protein (ASPM) was involved in the malignant proliferation and migration of glioma cells, and the expression of ASPM in glioma cells was positively correlated with Epothilone B sensitivity. In addition, recent studies found that ASPM can bind with AURKA, and our previous studies found that AURKA expression in glioma tissues is significantly positively correlated with ASPM expression. In U87-MG cells, inhibition of ASPM could significantly down-regulate AURKA protein expression and increase the Epothilone B sensitivity. Therefore, we hypothesize that ASPM may affect the sensitivity of Epothilone B by regulating the expression and activity of AURKA in glioma. Here, we plan to identify the correlation between ASPM and AURKA expression and the prognosis of glioma patients and Epothilone B sensitivity of glioma cells. Coimmunoprecipitation assay and GST-pulldown assay will be used to identify the interaction between ASPM and AURKA protein in glioma cells. Finally, cell and animal experiments will be applied to clarify the role of ASPM-mediated AURKA expression and activity regulation in Epothilone B resistance of glioma. This study will contribute to establish new potentially targets for glioma therapy and provide new insight for individualized treatment of glioma with Epothilone B resistance.
全基因组表达谱分析为探索肿瘤发生发展的机制提供了新的方法,可以有效识别参与肿瘤发生发展的致病基因。本项目通过生物信息学分析和临床样本验证发现ASPM在胶质瘤组织中异常高表达并提示患者较差的预后;干扰ASPM可以抑制胶质瘤细胞的增殖、迁移,诱导细胞周期阻滞,减缓胶质瘤裸鼠皮下肿瘤的生长;并首次揭示ASPM介导AURKA表达是调控胶质瘤发生发展的关键环节。Epothilone B 在胶质瘤治疗中具有良好的前景,在广泛的临床应用前揭示其疗效个体差异或抵抗机制对指导该药的临床试验或应用具有重要意义。本项目首次发现干预 ASPM 表达可以增加胶质瘤细胞对 Epothilone B 化疗敏感性,并提出ASPM可能通过影响AURKA介导 Epothilone B 化疗抵抗的分子机制。本研究可以为胶质瘤的个体化治疗提供科学依据,同时为Epothilone B 应用于治疗胶质瘤以及逆转 Epothilone B 化疗抵抗提供重要的药理学依据和思路。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma.
用于预测胶质母细胞瘤生存和药物化合物的新型血栓相关特征
DOI:10.1155/2022/6792850
发表时间:2022
期刊:Journal of oncology
影响因子:--
作者:
通讯作者:
Aberrant ASPM expression mediated by transcriptional regulation of FoxM1 promotes the progression of gliomas.
FoxM1转录调控介导的异常ASPM表达促进神经胶质瘤的进展
DOI:10.1111/jcmm.15435
发表时间:2020-09
期刊:Journal of cellular and molecular medicine
影响因子:5.3
作者:Zeng WJ;Cheng Q;Wen ZP;Wang JY;Chen YH;Zhao J;Gong ZC;Chen XP
通讯作者:Chen XP
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
免疫检查点PD-L1和CTLA-4在癌症中的调节机制
DOI:10.1186/s13046-021-01987-7
发表时间:2021-06-04
期刊:Journal of experimental & clinical cancer research : CR
影响因子:--
作者:Zhang H;Dai Z;Wu W;Wang Z;Zhang N;Zhang L;Zeng WJ;Liu Z;Cheng Q
通讯作者:Cheng Q
Identification of gene expression and DNA methylation of SERPINA5 and TIMP1 as novel prognostic markers in lower-grade gliomas
鉴定 SERPINA5 和 TIMP1 的基因表达和 DNA 甲基化作为低级别胶质瘤的新型预后标志物
DOI:10.7717/peerj.9262
发表时间:2020-06
期刊:PeerJ
影响因子:2.7
作者:Wen-Jing Zeng;Yong-Long Yang;Zhi-Peng Wen;Peng Chen;Xiao-Ping Chen;Zhi-Cheng Gong
通讯作者:Zhi-Cheng Gong
A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
泛癌症分析揭示 CLEC5A 作为癌症免疫和预后的生物标志物
DOI:10.3389/fimmu.2022.831542
发表时间:2022
期刊:Frontiers in immunology
影响因子:7.3
作者:
通讯作者:
国内基金
海外基金
